Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre
- 22 June 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Clinical Urology
- Vol. 16 (4) , 293-302
Abstract
This study aimed to provide real-world data on the multidisciplinary management of metastatic penile squamous-cell carcinoma (mpSCC) patients and their survival outcomes, particularly those who receive best supportive care (BSC). A retrospective analysis of 1720 patients, managed via a supra-regional penile-specialist multidisciplinary team was conducted between January 2006 and May 2020. A total of 101 patients (median age 63 years; interquartile range 56–72 years; 73% ECOG 0/1) were included. Of these, 32% (32/101) had previously received adjuvant chemotherapy prior to metastatic recurrence, 58% (59/101) received chemotherapy and 42% (42/101) received BSC. Further, 17% (17/101) received second-line systemic therapy, and 3% (3/101) received third-line systemic therapy. For first-line systemic-therapy, there was a 46% (27/59) clinical benefit rate (CBR), with 9% (5/59) complete response, 15% (9/59) partial response and 22% (13/59) stable disease. Patients receiving second-line therapy (n=17) had a 29% (5/17) CBR. Median progression-free survival for first- and second-line treatment was 3.2 and 2.2 months, respectively. Median overall survival (mOS) for all patients was 6.2 months. mOS for first-line chemotherapy, second-line chemotherapy and BSC patients was 7.2, 4.5 and 2.0 months, respectively. First-line platinum-based chemotherapy is associated with notable response rates in mpSCC patients. Agents with better response rates are needed urgently potentially in combination with platinum-based chemotherapy. Level 2b.Keywords
This publication has 20 references indexed in Scilit:
- EAU Guidelines on Penile Cancer: 2014 UpdateEuropean Urology, 2015
- Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapyUrologic Oncology: Seminars and Original Investigations, 2014
- Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)British Journal of Cancer, 2013
- Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologistsUrologic Oncology: Seminars and Original Investigations, 2013
- Multiple Cutaneous Metastasis from Carcinoma of the Penis—Report of Two CasesIndian Journal of Surgical Oncology, 2013
- Penile cancer: current therapy and future directionsAnnals of Oncology, 2013
- Cisplatin and 5‐fluorouracil in inoperable, stage IV squamous cell carcinoma of the penisBJU International, 2012
- Paclitaxel in Pretreated Metastatic Penile Cancer: Final Results of a Phase 2 StudyEuropean Urology, 2011
- Treatment of Visceral, Unresectable, or Bulky/Unresectable Regional Metastases of Penile CancerUrology, 2010
- Taxanes in Combination with Cisplatin and Fluorouracil for Advanced Penile Cancer: Preliminary ResultsEuropean Urology, 2009